RPRT1 - Overview: Rapid Plasma Reagin (RPR) Screen with Reflex to Titer, Serum

Determining the current disease status Monitoring response to therapy for syphilis Aid to diagnose congenital syphilis This test cannot be used for testing spinal fluid specimens. This test is not intended for medical-legal use.

RPRT3 - Overview: Rapid Plasma Reagin (RPR) with Reflex to Treponema pallidum Particle Agglutination, Serum

Diagnosing syphilis

CTXWB - Overview: Cerebrotendinous Xanthomatosis, Blood

Evaluating patients with a clinical suspicion of cerebrotendinous xanthomatosis (CTX) Monitoring of individuals with CTX on chenodeoxycholic acid (CDCA) therapy This test is not useful for the identification of carriers. This test is...

OXU - Overview: Oxalate, 24 Hour, Urine

Monitoring therapy for kidney stones using 24-hour urine collections Identifying increased urinary oxalate as a risk factor for stone formation Diagnosis of primary or secondary hyperoxaluria

FCDU2 - Overview: Benzodiazepines, Umbilical Cord Tissue

Benzodiazepines, Umbilical Cord Tissue

FCDU1 - Overview: Opiates, Umbilical Cord Tissue

Opiates, Umbilical Cord Tissue

HMU24 - Overview: Heavy Metals Screen, with Reflex, 24 Hour, Urine

Detecting arsenic, cadmium, mercury, and lead exposure and toxicity using 24-hour urine specimens

G6PD1 - Overview: Glucose 6-Phosphate Dehydrogenase Enzyme Activity, Blood

Evaluation of individuals with episodic or chronic Coombs-negative nonspherocytic hemolytic anemia Rapid testing to assess glucose 6-phosphate dehydrogenase (G6PD) enzyme capacity prior to rasburicase or other therapies that may cause...

PBCPN - Overview: Primary Biliary Cholangitis Antibody Panel, Serum

Evaluation of at-risk or previously diagnosed primary biliary cholangitis patients with new features of other liver diseases or systemic autoimmune diseases

ECMP - Overview: Eculizumab Monitoring Panel, Serum

Monitoring of complement blockage by eculizumab Assessing the response to eculizumab therapy Assessing the need for dose escalation Evaluating the potential for dose de-escalation or discontinuation of therapy in remission...